SCHEMBL2298577

SCHEMBL2298577

Nc1ccc(CC(=O)O)c(F)c1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
AKR1B1 P15121 2/20 0.43
HPGD P15428 2/20 0.42
CYP2C19 P33261 2/20 0.42
ADRA2B P18089 1/20 0.42
CYP2C9 P11712 1/20 0.42
CXCL8 P10145 2/20 0.41
TSHR P16473 1/20 0.39
SRC P12931 1/20 0.39
PTGER4 P35408 1/20 0.38
CYP26A1 O43174 1/20 0.38
CYP26B1 Q9NR63 1/20 0.38
CYP1A2 P05177 1/20 0.38
FFAR1 O14842 1/20 0.37
FFAR4 Q5NUL3 1/20 0.37
MEN1 O00255 1/20 0.37
USP2 O75604 1/20 0.37
POLB P06746 1/20 0.37
MAPT P10636 1/20 0.37
THRB P10828 1/20 0.37
PKM P14618 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Malonic Acid SCHEMBL3810427 0.95 AKR1B1 (0.43) AKR1B1HPGDCYP2C19ADRA2BCYP2C9
SCHEMBL2788693 0.85 HPGD (0.42) AKR1B1HPGDCYP2C19CYP2C9CXCL8
SCHEMBL2745778 0.84 MAPT (0.53) AKR1B1HPGDCYP2C19CYP2C9TSHR
SCHEMBL14221079 0.82 HPGD (0.46) AKR1B1HPGDCYP2C19CYP2C9SRC
SCHEMBL4611520 0.81 FFAR1 (0.56) HPGDCYP2C19FFAR1FFAR4POLB
SCHEMBL27877180 0.80 FFAR1 (0.48) AKR1B1HPGDCYP2C19FFAR1FFAR4
SCHEMBL29459931 0.80 TSHR (0.53) AKR1B1CXCL8TSHR
SCHEMBL503325 0.80 TSHR (0.53) AKR1B1CXCL8TSHR
SCHEMBL29393814 0.80 HPGD (0.45) AKR1B1HPGDCYP2C19CYP2C9SRC
SCHEMBL987449 0.80 HPGD (0.45) AKR1B1HPGDCYP2C19CYP2C9SRC

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 37 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-103012111-A Preparation method 2,4,5-trifluorophenylacetic acid UNIV QUZHOU 2013-04-03 CN claimed
US-20210171471-A1 Benzimidazole Derivatives as Modulators of Retinoid-Related Orphan Receptor Gamma (RORy) and Pharmaceutical Uses Thereof JIANGSU HENGRUI MEDICINE CO., LTD. (CN) 2021-06-10 US disclosed
CN-103012111-B A kind of preparation method of 2,4,5-trifluoro benzene acetic acid QUZHOU UNIVERSITY (CN) 2016-01-13 CN disclosed
WO-2014125426-A1 TRISUBSTITUTED HETEROCYCLIC DERIVATIVES AS ROR GAMMA MODULATORS AURIGENE DISCOVERY TECHNOLOGIES LIMITED (IN) 2014-08-21 WO disclosed
WO-2014125426-A1 TRISUBSTITUTED HETEROCYCLIC DERIVATIVES AS ROR GAMMA MODULATORS AURIGENE DISCOVERY TECHNOLOGIES LIMITED (IN) 2014-08-21 WO disclosed
EP-2098517-B1 NOVEL PHENYL-ISOXAZOL-3-OL DERIVATIVE MSD KK (JP) 2013-12-18 EP disclosed
US-20130261185-A1 Benzamide Derivatives As EP4 Receptor Agonists GLAXO GROUP LIMITED (GB) 2013-10-03 US disclosed
CN-103012111-A Preparation method 2,4,5-trifluorophenylacetic acid UNIV QUZHOU 2013-04-03 CN disclosed
WO-2013029338-A1 NOVEL COMPOUNDS GLAXO GROUP LIMITED (GB) 2013-03-07 WO disclosed
US-8367708-B2 Phenyl-isoxazol-3-ol derivative MSD K.K. (JP) 2013-02-05 US disclosed
CN-101415678-A Benzo (F) isoindol-2-ylphenylacetic acid derivatives as EP4Receptor agonists GLAXO GROUP LTD (GB) 2009-04-22 CN disclosed
EP-1979317-A1 BENZOISOINDOLE DERIVATIVES FOR THE TREATMENT OF PAIN GLAXO GROUP LIMITED (GB) 2008-10-15 EP disclosed
EP-1979316-A1 BENZO (F) ISOINDOL-2-YLPHENYL ACETIC ACID DERIVATIVES AS EP4 RECEPTOR AGONISTS GLAXO GROUP LIMITED (GB) 2008-10-15 EP disclosed
US-20080167377-A1 Novel compounds GLAXO GROUP LIMITED (GB) 2008-07-10 US disclosed
WO-2008071736-A1 BENZAMIDE DERIVATIVES AS EP4 RECEPTOR AGONISTS GLAXO GROUP LIMITED (GB) 2008-06-19 WO disclosed
WO-2007088189-A1 BENZOISOINDOLE DERIVATIVES FOR THE TREATMENT OF PAIN GLAXO GROUP LIMITED (GB) 2007-08-09 WO disclosed
WO-2007088190-A1 BENZO (F) ISOINDOL-2-YLPHENYL ACETIC ACID DERIVATIVES AS EP4 RECEPTOR AGONISTS GLAXO GROUP LIMITED (GB) 2007-08-09 WO disclosed
WO-2007088190-A1 BENZO (F) ISOINDOL-2-YLPHENYL ACETIC ACID DERIVATIVES AS EP4 RECEPTOR AGONISTS GLAXO GROUP LIMITED (GB) 2007-08-09 WO disclosed
US-4333940-A Ring-fluorinated 4-(monosubstituted-amino) phenyl compounds in inhibiting atherosclerotic lesion development AMERICAN CYANAMID COMPANY (US) 1982-06-08 US disclosed
US-4243609-A ANTILIPEMIC AGENTS, ANTIATHEROSCLEROTIC AGENTS AMERICAN CYANAMID COMPANY (US) 1981-01-06 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080167377-A1 Novel compounds F12, C1R, MRGPRX1 AKR1B1 1541/4885HPGD 2744/4885CYP2C19 103/4885
US-20210171471-A1 Benzimidazole Derivatives as Modulators of Retinoid-Related Orphan Receptor Gamma (RORy) and Pharmaceutical Uses Thereof RORB, RORA, RORC AKR1B1 420/4885HPGD 1858/4885CYP2C19 380/4885
US-20130261185-A1 Benzamide Derivatives As EP4 Receptor Agonists PTGER4, PTGER1, PTGER3 AKR1B1 1653/4885HPGD 748/4885CYP2C19 317/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.